Skip to main content

Neurosciences

Title
 Adult Neurosurgery, Service Specification, (CP178), March 2023 (PDF, 731Kb)
 Bevacizumab for the treatment of vestibular schwannomas in Neurofibromatosis Type 2 (now known as NF2-related vestibular schwannomatosis) (all ages) (CP254), August 2023 (PDF, 440Kb)
 CP22 Stereotactic Radiosurgery for Adults, Teenagers and Young Adults (TYA) (CP22) June 2026 (PDF, 455Kb)
 Deep Brain Stimulation, Commissioning Policy (CP28), July 2024 (PDF, 384Kb)
 Inherited White Matter Disorders Policy Position Statement (PP239) May 2023 (PDF, 565Kb)
 Mechanical Thrombectomy for the treatment of acute Ischaemic Stroke, Commissioning Policy (CP168). March 2025 (PDF, 887Kb)
 Neuropsychiatric Rehabilitation (Specialised), Commissioning Policy, (CP128), August 2024 (PDF, 327Kb)
 Odevixibat for Treating Progressive Familial Intrahepatic Cholestasis, Policy Position Statement, (PP249), February 2023 (PDF, 193Kb)
 Pipeline Embolisation Devices used for the treatment of Intracranial Aneurysms (Complex Giant or Large Intracranial Aneurysms), Commissioning Policy (CP101). July 2015 (PDF, 352Kb)
 Plerixafor for stem cell mobilisation, Policy Position Statement (PP154), July 2024 (PDF, 208Kb)
 Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over, Policy Position Statement (PP267), September 2023 (PDF, 228Kb)
 Specialist Spinal Cord Injury Rehabilitation, Commissioning Policy (CP141). February 2025 (PDF, 438Kb)
 Specialist Neurological Rehabilitation, Commissioning Policy (CP140), November 2024 (PDF, 433Kb)
 Transcranial magnetic resonance guided focused ultrasound (TcMRgFUS) thalamotomy for treatment of medication-refractory essential tremor for people aged 18 and over, Policy Position Statement, (PP258), August 2023 (PDF, 298Kb)
 Vagal Nerve Stimulation, Commissioning Policy (CP23), July 2023 (PDF, 688Kb)
 Welsh Artificial Eye Service (WAES) (All Ages), Service Specification (CP238), December 2022 (PDF, 453Kb)